Skip to content

Segmental Mechanisms of Transcutaneous Spinal Cord Stimulation for Spasticity Control

Carry-over Effects of Transcutaneous Spinal Cord Stimulation for Spasticity Control on Inhibitory Circuits of the Spinal Cord: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03886857
Acronym
SCS_CorE_AT
Enrollment
30
Registered
2019-03-22
Start date
2019-05-01
Completion date
2022-10-01
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Brief summary

The aim of the pilot study is to gain first insights into the interaction of transcutaneous spinal cord stimulation with the altered activity of intraspinal circuits associated with spinal spasticity. The main goal is to evaluate the validity of the chosen measures and to generate a data base for statistical planning of a subsequent clinical study.

Interventions

DEVICEtranscutaneous spinal cord stimulation

noninvasive electrical stimulation of the human lumbar spinal cord

Sponsors

Medical University of Vienna
CollaboratorOTHER
Peter Lackner
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

written informed consent prior to participation for participants with intact CNS: • no previous neurological or musculoskeletal disorders for participants with spinal cord injury: * Spinal cord injury due to trauma * ≥ 12 months post-spinal cord injury * complete or incomplete spinal cord injury classified as grade C or D on the American Spinal Injury Association Impairment Scale (AIS) * neurological level of spinal cord injury: C3-T10 * preserved tendon and cutaneo-muscular reflexes in the lower limbs

Exclusion criteria

* other neuromuscular diseases, e.g., amyotrophic lateral sclerosis (ALS), Parkinson's disease, Guillain-Barré syndrome, muscular dystrophy * active implants (e.g., cardiac pacemaker, drug pump) * passive implants at vertebral level T10 or caudal (e.g., metal screws/plates for surgical stabilization of spinal fractures) * active infections or diseases, pressure sores * dermatological issues at the stimulation site * malignant diseases * heart insufficiency (NYHA III-IV) * potential pregnancy (pregnancy test to be conducted in women of child bearing age before application of transcutaneous spinal cord stimulation)

Design outcomes

Primary

MeasureTime frameDescription
Postsynaptic inhibitionpre-intervention to 2 hours post-interventionreciprocal inhibition of the soleus H-reflex

Secondary

MeasureTime frameDescription
Presynaptic inhibitionpre-intervention to 2 hours post-interventioninduced D1 inhibition and ongoing presynaptic inhibition of the soleus-H reflex
H_max/M_maxpre-intervention to 2 hours post-interventionRatio of the maximum H reflex and the maximum M wave
Low-frequency depressionpre-intervention to 2 hours post-interventionrate-dependent depression of the soleus H-reflex
Evaluation of lower-limb spasticitypre-intervention to 2 hours post-interventionsurface-electromyography based assessments

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026